A Collaborative Working Project between Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust and Alimera Sciences Ltd
Optimising intravitreal treatment pathways for Diabetic Macular Oedema patients through analysis of non-attendance and multidisciplinary Intervention
Executive Summary
This project is a Collaborative Working initiative as defined by the ABPI Code of Practice. Its primary aim is to improve patient outcomes and support NHS service delivery. The project is non-promotional in nature.
Bristol Eye Hospital Retina Services face capacity and efficiency constraints, with approximately 10% non-attendance for intravitreal therapy appointments, leading to delayed treatment, reduced clinic productivity, and increased risk of avoidable vision loss for patients with diabetic macular oedema (DMO).
This proposal has been developed in partnership between Bristol Eye Hospital and Alimera Sciences Ltd to analyse attendance patterns, identify repeat non-attendance, and understand patient-reported barriers to engagement. Findings will inform targeted interventions across patient communication, education, consent processes, and pathway design to improve efficiencies and patient outcomes.
Where clinically appropriate the project will consider treatment strategies in line with clinical judgement and local and national guidance to help reduce treatment burden and support adherence for patients.
All treatment decisions remain solely the responsibility of the treating clinician. This project does not influence prescribing decisions. No specific medicine or manufacturer will be promoted or preferred as part of this project.
This project is overseen jointly by Bristol Eye Hospital and Alimera Sciences Ltd, with a defined governance framework led by Bristol Eye Hospital, including appropriate oversight and review processes. All clinical and service decisions remain under the sole governance of the NHS organisation.
Alimera Sciences Ltd provides funding and in-kind support for project management and service improvement activities. Any transfers of value will be disclosed in line with ABPI transparency requirements.
Intended Benefits
| For Patients | Care delivered through more predictable and reliable appointment pathways, improving continuity of treatment and reducing delays. Improved understanding of disease and treatment through enhanced education and communication. Reduced treatment burden where appropriate through service, pathways ad treatment optimization and improved experience through streamlined follow-up pathways. |
| For the NHS | Increased capacity within BEH retina clinics through reduced wasted appointments and more efficient use of existing resources. Improved patient flow and support for development of dedicated DMO pathways in line with national and local priorities. |
| For Alimera Sciences Ltd | Will gain a closer understanding of the development and implementation of new models of care and the patient pathways in relation to non- attendance in Diabetic Macular Oedema Services. Demonstrate the value that Alimera Sciences Ltd can bring by collaborating with the NHS to improve patient outcomes and treatment pathways. More holistically supported Diabetic Macular Oedema patents might have a higher chance of completing and benefiting from their respective treatments through better adherence. |
This project is expected to run for up to 18 months, with regular review points to ensure alignment with its objectives
For further information please contact
Alimera Sciences Limited
An ANI Pharmaceuticals, Inc. Company
Form 1 Bartley Wood Business Park, Hook, Hampshire, RG27 9XA, UK
Registered in England & Wales: 08018355
www.alimerasciences.eu
t + 44 (0) 1252354027